The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
T2T Validation - Endolysosomal Targets, 2025In Vivo Efficacy of a TRPML1 Activating Compound in Alpha-synuclein PD Pre-clinical Models
Study Rationale: Many genes harboring mutations that increase the risk for developing Parkinson’s disease (PD) are associated with the cell’s recycling center, the lysosome. Compounds activating the...
-
T2T Validation - Endolysosomal Targets, 2025Development of in Vivo Biomarkers for TRPML1 Target Engagement and Analysis of Therapeutics
Study Rationale: The appropriate regulation of proteins and lipids within neurons is critical for human health. Lysosomes are specialized structures within cells that are responsible for the removal...
-
Parkinson’s Disease Therapeutics Pipeline Program, 2025IND-enabling Studies of a Promising USP30 Inhibitor as Disease-modifying Therapy for Parkinson's Disease
Study Rationale: While the cause of Parkinson's disease (PD) remains unknown for most patients, strong evidence indicates that damaged mitochondria in neurons likely play a causal role. Mitochondria...
-
Research Grant, 2025Clinical Development of the PET Tracer Candidate MODAG-009 for quantitative Detection of Alpha-synuclein Pathology in Parkinson’s Disease
Study Rationale: In both Parkinson's disease and multiple system atrophy (MSA), the protein alpha-synuclein becomes altered, resulting in the accumulation of clumps of aggregated alpha-synuclein in...
-
Research Grant, 2024SUPPLEMENT: MJFF Consortium on PRKN and PINK1
Study Rationale: Recessively inherited forms of Parkinson’s disease (PD) caused by mutations on both copies of the genes PRKN and PINK1 are unique in many aspects. Age at onset is mainly before the...
-
Research Grant, 2024Virtual Screening and Biochemical Confirmation of Small Molecule Activators of ATP10B
Study Rationale: Disruption of lysosomal glucosylceramide (GluCer) homeostasis is a key risk factor in Parkinson’s disease. ATP10B, a lysosomal GluCer exporter, has been linked to Parkinson’s through...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.